Moderna Inc. (MRNA)
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 8, 2024 in Moderna, Inc. Lawsuit - MRNA
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Biotechnology company Moderna Inc. NASDAQ: MRNA stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. The company disappointed investors when it revised its respiratory franchise revenue forecast lower by half a billion dollars.
Shareholders That Lost Money on Moderna, Inc. (MRNA) Should Contact Levi & Korsinsky About Pending Class Action - MRNA
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna Stockholders Encouraged To Join The Securities Fraud Lawsuit Against Moderna Inc. With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.
Shareholders That Lost Money on Moderna, Inc. (MRNA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Moderna, Inc. of Class Action Lawsuit and Upcoming Deadlines – MRNA
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 24-cv- 12058, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Moderna securities between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Levi & Korsinsky Notifies Shareholders of Moderna, Inc. (MRNA) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
MRNA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the "Class Period").
Moderna, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your Rights - MRNA
NEW YORK, NY / ACCESSWIRE / August 18, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your Rights - MRNA
NEW YORK, NY / ACCESSWIRE / August 18, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Shareholders of Moderna, Inc. Should Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your Rights - MRNA
NEW YORK, NY / ACCESSWIRE / August 18, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna Investors Invited To Be A Part Of Securities Fraud Lawsuit Against Moderna Inc. With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.
